RADNOR, Pa., April 26, 2022 /PRNewswire/ — Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, announced that Michael Stubblefield, President and CEO, will be participating in a fireside chat at the BofA Securities 2022 Healthcare Conference in Las Vegas on Tuesday, May 10, 2022 at approximately 12:20 p.m. Eastern Daylight Time.
A live webcast can be accessed on the investors section of our website and a replay will be available for approximately 90 days.
About Avantor
Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. For more information, please visit www.avantorsciences.com.
Media Contact
Allison Hosak
Senior Vice President, Global Communications and Brand
Avantor
908-329-7281
Allison.Hosak@avantorsciences.com
Investor Relations Contacts
Tommy Thomas
Vice President, Investor Relations
Avantor
781-375-8051
Tommy.Thomas@avantorsciences.com
Christina Jones
Vice President, Strategy
Avantor
805-617-5297
Christina.Jones@avantorsciences.com
View original content:https://www.prnewswire.com/news-releases/avantor-to-participate-in-bofa-securities-2022-healthcare-conference-301532394.html
SOURCE Avantor and Financial News
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…